Logo

BGI Genomics Nabs CE Mark for Colorectal Cancer Screening Test

May 19, 2021 | staff reporter

NEW YORK – BGI Genomics announced on Wednesday that its colorectal cancer screening test has received CE marking.

The DNA Methylation Detection Kit for Human SDC2, ADHFE1, and PPP2R5C Genes can detect abnormal methylation of the genes in stool DNA from human fecal samples. The genes are highly specific markers for colorectal cancer cells, the company said in a statement.

The noninvasive test is intended to help diagnose patients who are recommended by clinicians to receive a diagnostic colonoscopy.

Shenzhen, China-based BGI Genomics is the clinical genetic testing and research services arm of China's BGI Group.

Filed under

Cancer
Regulatory News & FDA Approvals
Molecular Diagnostics
Europe
methylation
CE mark
BGI
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.